Stock 688105 NANJING VAZYME BIOTECH CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Nanjing Vazyme Biotech Co.,Ltd

Equities

688105

CNE100004ZK3

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
23.49 CNY -1.30% Intraday chart for Nanjing Vazyme Biotech Co.,Ltd -4.63% -26.64%
Apr. 26 Nanjing Vazyme Biotech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 15 Nanjing Vazyme Biotech Unit Gets Nod to Register Six Medical Devices; Shares Slump 14% MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The group's high margin levels account for strong profits.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
NANJING VAZYME BIOTECH CO.,LTD Stock Nanjing Vazyme Biotech Co.,Ltd
-26.64% 1.29B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 727B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+33.05% 599B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 328B
B-
ABBVIE INC. Stock AbbVie Inc.
+1.35% 277B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 243B
B+
NOVARTIS AG Stock Novartis AG
+8.09% 205B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-5.77% 203B
A+
AMGEN INC. Stock Amgen Inc.
+6.19% 164B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 688105 Stock
  4. Ratings Nanjing Vazyme Biotech Co.,Ltd